AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AMRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AMRX | Board Member; Director | 73 | ["Former President and CEO at Teva Pharmaceutical Industries Ltd.", "Former CEO of Adama Industries", "Chairman of the Board of Lumenis Ltd.", "Senior advisor to Moelis & Company", "Various leadership positions in the Israel Defense Forces", "Graduate of Harvard Business School\u2019s AMP program", "Master of Public Administration from George Washington University", "B.A. degree from Tel Aviv University"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PM | Director; Chairman of the Board | 73 | ["Chairman of the Board at Lumenis Ltd.", "Senior Advisor at Moelis & Company since 2016", "President and CEO at Teva Pharmaceuticals Industries Ltd. from 2007 to 2012", "CEO at Adama Industries from 2002 to 2006", "Leadership roles in Israeli Defense Forces for 32 years, retiring as Major General", "Received Israel\u2019s Medal of Valor in 1973"] | ["Nominating and Corporate Governance Committee", "Science And Technology Committee", "Compensation &LeadershipDevelopment", "Science and Technology", "Nominating and Corporate Governance"] | 2026 |
| PRGO | Former Executive | [] | [] | 2016 |
Biography sourced from the proxy statement filing.
Shlomo Yanai has served on our Board of Directors since December 2019. Mr. Yanai has more than 17 years of corporate leadership experience, primarily in the pharmaceutical industry. Mr. Yanai served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Prior to that, Mr. Yanai was the CEO of Adama Industries from 2002 to 2006. Mr. Yanai currently serves as the Chairman of the Board of Lumenis Ltd., a Board member at Philip Morris, and a senior advisor to Moelis & Company. Mr. Yanai previously served as Vice Chairman of the Rothschild Caesarea Foundation, Chairman of the Board of Cambrex Corporation and director of Protalix Biotherapeutics, PDL BioPharma Inc., Perrigo Company, Sagent Pharmaceuticals, Elisra, Bank Leumi Lelsreal, and I.T.L. Optronics Ltd. and a Board member of W. R. Grace from 2018-2021. Mr. Yanai also held various leadership positions in the Israel Defense Forces. Mr. Yanai is a graduate of Harvard Business School's AMP program. He holds a Master of Public Administration degree from George Washington University and a B.A. degree from Tel Aviv University and is also a graduate of the U.S. National Defense University War College. Skills and Qualifications: CEO, General Management, Commercial Investment, Venture Capital